The news from Oxford and Wuhan is encouraging for both teams, but no scope for high-fives.
After a week of high geopolitical drama - that started with China and Iran moving into an-all-too-inevitable embrace in the Middle East before Britain dropped Huawei from their 5G network, irritated Beijing over Hong Kong and the BBC called in the Chinese Ambassador in London to their studios for an ambush interview - the match has already been lit for yet more maneuvering, and it looks like this time we're headed back to the Coronavirus.
The Lancet, the most esteemed journal of medical science, published two studies reporting the findings of two separate Coronavirus vaccine trials: from Britain, the candidate that has come to be known as the 'Oxford vaccine' owing to its base at the Jenner Institute at Oxford University, with support from AstraZeneca, and the second from investigators supported by CanSino Biologics in Wuhan, China.
Both groups used an adenoviral vector, and both report the vaccine achieving humoral responses to the SARS-CoV-2 spike glycoprotein receptor binding domain by day 28 as well as T-cell responses. Both report local and systemic mild adverse events such as fever, fatigue, and injection site pain. In neither trial was a severe adverse event reported.
Andrew Pollard and colleagues report their phase 1/2 randomised trial of one injection of chimpanzee adenovirus-vectored COVID-19 vaccine. Vaccine formulation at one concentration was tested against a comparator quadrivalent conjugate meningococcal vaccine among 1077 healthy adults (50% male, 90•9% white) aged 18-55 years (median 35 years, IQR 28-44), recruited from five centres in the UK and followed up for 28 days. Local and systemic adverse events such as fatigue, headache, and local tenderness occurred commonly in COVID-19 vaccinees, but were tolerable and mostly ameliorated by paracetamol. No serious adverse events occurred. Neutralising antibodies were generated in more than 90% of participants across different assays. Responses were sustained up to 56 days of observation. A small non-randomly selected, second-dose boosted subset showed strong neutralising responses, and few mild adverse events. Importantly, T-cell responses were induced in all participants.
Wei Chen and colleagues report results from a phase 2 randomised trial of one injection of non-replicating adenovirus-vectored COVID-19 vaccine. Vaccine formulation at two concentrations (ie, 1 × 1011 or 5 × 1010 viral particles per mL) were tested against placebo among 508 healthy COVID-19 unexposed adults (50% male) aged 18-83 years (mean 39•7 years) recruited from one centre in Wuhan, China, and followed up for 28 days. Adverse events such as fever, fatigue, headache, or local site pain occurred by day 28 in 294 (77%) of 382 vaccinees and 61 (48%) of 126 placebo recipients. Male sex was associated with lower occurrence of fever post-vaccination. No serious adverse events occurred.
Seroconversion occurred in more than 96% of participants, and neutralising antibodies were generated in about 85%. More than 90% had T-cell responses. People older than 55 years of age had somewhat lower humoral responses (although still higher than placebo), as did people with previous vector immunity, but these factors did not affect T-cell responses. Immunogenicity did not differ by sex.
These trial reports were hugely anticipated. The results of both studies augur well for phase 3 trials, where the vaccines must be tested on much larger populations of participants to assess their efficacy and safety. Overall, the results of both trials are broadly similar and promising, notwithstanding differences in the vector, in the geographical locations of the populations studied, and the neutralisation assays used.
Without drawing causal inference, the exploration of associations of age and sex with adverse events and immunogenicity reported by Chen and colleagues, and of longevity of response by Pollard and colleagues, are welcomed, given the differential burden of severe outcomes in older adults, and the emerging science around differential sex-specific vaccine effects. These COVID-19 vaccine trials are small so inferential caution is warranted, but the explorations are laudable. Ethnic diversity in both these trials was very limited.
Sticking to science
Both trials used adenovirus vectors to deliver and study the COVID-19 vaccine, an innovative and efficient means of vaccine development in the midst of a pandemic. Capable of generating humoral, cellular, and innate responses, adenovirus-vectored vaccines have much potential. The platform only achieved European Commission regulatory licensure on July 1, 2020, with the Ebola vaccine. Much remains unknown about these and other COVID-19 vaccines in development, including longevity of response and immunogenicity in older adults or other specific groups, such as those with comorbidities who are often excluded from clinical trials, or ethnic or racial groups more severely affected by COVID-19.
What should phase 3 trials look like? They should be rapid, pragmatic, and large enough to address efficacy in subgroups of interest, according to The Lancet. Will a single dose be sufficient in older adults, or is a booster dose required? Does longevity of response or rates of waning differ with a two-dose regimen, and does longevity of clinical protection require cell-mediated responses? Are there host-specific differences in immunogenicity by age, sex, or ethnicity? Do T-cell responses correlate with protection irrespective of humoral titres? Are there specific adverse events in pregnant women? As hotspots for infection shift, trial designs that are responsive to differential risk, or that are enriched for networks of infection, should be deployed.
The safety signals from these two important trials are reassuring. But when things are urgent, we must proceed cautiously. The success of COVID-19 vaccines hinges on community trust in vaccine sciences, which requires comprehensive and transparent evaluation of risk and honest communication of potential harms. Hand in hand with the trajectory of vaccine study, pharmacovigilance infrastructure is urgently needed, including surveillance for asymptomatic infection among vaccinated and unvaccinated persons if both absolute and relative risk of adverse vaccine outcomes, such as enhanced disease, are to be determined. These should be implemented in parallel with phase 3 trials and in preparation for phase 4 roll-out. Such infrastructure will be needed across a wide range of populations and settings, and for the spectrum of upcoming COVID-19 vaccines.
Equitable distribution of future COVID-19 vaccines also requires detailed evaluation of local country needs and priorities, community engagement, and trust. Global planning is underway, but should be underpinned and informed by specific local realities. Only this way can these very encouraging first early-phase randomised trial results yield the global remedy for which we all yearn.
Even though The Lancet published the reports on the same day, there was a distinct and very deliberate myopia among the two principal groups of stakeholders. The media in the UK largely ignored the results from Wuhan, and China's constellation of English-language outlets largely did the same for the Oxford one.
It was ironic that officials from the two countries were still going at it over Huawei and Hong Kong. Some headlines from the Global Times landing page on Monday gives some idea: Beijing may target British companies if 10 Downing Street sanctions China, Little effect on China as UK ends extradition treaty with HKSAR to please US, Chinese investment will be cautious as UK leans to US, and Huawei not a 'China First' case to be confused with America First.
After intensive research, Prof Sarah Gilbert, from Oxford's Jenner Institute, said they were more than happy with the first results, which showed good immunity after a single dose of vaccine.
"We're really pleased that it seems to be behaving just as we thought it would do. We have quite a lot of experience of using this technology to make other vaccines, so we knew what we expected to see, and that's what we have seen," she told the Guardian.
The British prime minister, Boris Johnson, called the results "very positive news", adding: "There are no guarantees, we're not there yet and further trials will be necessary - but this is an important step in the right direction."
His health secretary, Matt Hancock, said: "Very encouraging news. We have already ordered 100 million doses of this vaccine, should it succeed."
Gilbert and her colleagues, who once said they could have a vaccine by September, will not predict when it might be available. "None of us have a crystal ball," she said.
Leave a Comment
If you stumbled on the scene too late, you might have missed him there ...
Climate Crisis is one of the most vogue crises people are facing in th ...